Patients were randomly assigned to intravitreal ranibizumab 0.3 mg (n=51), intravitreal ranibizumab 0.5 mg (n=51) or sham injection (n=49). In this study, patients underwent a 3 month dose-loading phase after which treatment could be stopped or re-initiated with rescue laser photocoagulation. After the first month, dose-doubling in the 0.05mg arm was permitted.

Quiz Module 10.2

1. The RESOLVE study showed that:

2. RESOLVE was the first study to allow: